AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06721975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium Laser Fiber (TFL)
Description: The thulium fiber laser (TFL) has demonstrated effectiveness in this procedure
Study NCT06720649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic test
Description: Bilateral strength will be measured using a Contrex ® dynamometer equipped with an exercise table. Each subject will perform isokinetic tests of the right and left knee extensors and flexors. Subjects will be stabilized by straps during testing and the joint rotation axis will be aligned with the input shaft of the dynamometer.
Study NCT02245945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV 1% vaginal gel
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
Study NCT02245945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel
Description: Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
Study NCT05932979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
Study NCT06720649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballistic test
Description: ballistic squat jumps performed in the supine position on a frictionless sled at a resistance between 0% of body weight (BW)
Study NCT06720649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: K-STARTS test
Description: The K-STARTS (Knee Health Athletic Return To Sport) test brings together a set of 7 tests validated in the scientific literature to assess the control and neuromuscular capacities of the lower limb when performing dynamic movements as well as apprehension when resuming activity.~Test in 30 minutes with physical exercises and questionnaire.
Study NCT05932979 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch
Study NCT04877405 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This observational study is not focused on therapeutic intervention
Study NCT06720649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: KOOS (Knee Injury and Osteoarthritis Outcome Score) Questionnaire
Study NCT06721793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate electrolyte drink
Description: 2% carbohydrate solution with 1,020 mg/L of Sodium
Study NCT06721793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no-sugar electrolyte drink
Description: 1% carbohydrate solution with 1,060 mg/L of Sodium
Study NCT06721793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeinated Carbohydrate and electrolyte drink
Description: 2% carbohydrate solution with 1,000 mg/L of Sodium, and 200mg/L caffeine
Study NCT05838768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRO761
Description: Tablet
Study NCT05838768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Concentrate for solution for infusion
Study NCT05838768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Concentrate for solution for infusion
Study NCT05205291 — intervention group
Intervention type: DRUG
Intervention: Lipopolysaccharide
Description: All participants will receive one dose of Lipopolysaccharide (1ng/Kg) after the first PET/MR scan with \[11C\]PBR28 and four hours before the second PET/MR scan with \[11C\]PBR28.
Study NCT05205291 — intervention group
Intervention type: RADIATION
Intervention: PET/MR with [11C]PBR28
Description: A PET/MR scan using the tracer \[11C\]PBR28 will be performed to all participants before and four hours after the administration of LPS
Study NCT04587050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Human papillomavirus testing
Description: HPV test from cervical sample using Cepheid GeneXpert HPV
Study NCT04587050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical cytology
Description: Cervical cytology
Study NCT04587050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPV serology
Description: HPV type specific serology (16/18) using ELISA from serum samples
Study NCT05639296 — intervention group
Intervention type: OTHER
Intervention: Discovery learning (DL)
Description: DL makes the trainee practice before giving them instruction, Do-Then-Tell, thereby promoting their ability to use and build upon their existing knowledge.
Study NCT04529941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Implant with Active Treatment
Description: ScNS at 3.5mA output for 2 weeks
Study NCT04529941 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device Implant without Active Treatment
Description: No device output for 2 weeks
Study NCT05534399 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intra-vesical BoNTA injections
Description: Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure.
Study NCT05534399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-vesical BoNTA injections
Description: Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department.~They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields.~A rigid or a flexible cystoscope will be used.~After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand.~BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution~The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle.~A complete bladder emptying will be performed at the end of the procedure.
Study NCT06721793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water (Placebo)
Description: flavored water with non-caloric, non-sodium-containing sweetner
Study NCT06720129 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: the modified pressure-reducing fixation protective nasal strip
Description: Materials Preparation consists of one foam dressing, one piece of 3M tape, and two pairs of scissors. 2. Manufacturing Procedure: step 1 Cut the foam dressing into two large rectangles and one little T-shape based on the patient's face shape and size as well as the width of the nasolabial fold. Attach these sections to the nasolabial fold region and both cheeks, respectively . Step 2: Based on the size of the oxygen cannula, set up small, medium, and large fixation patch models. Select the appropriate model according to the patient's condition and make the necessary cuts to properly secure the nasal prongs. Step 3: Check the tightness of the head strap, ensuring it is snug enough to fit one finger beneath it to avoid pressing on the skin around the ears. Ensure proper placement on the patient. See Figure 1 for detailed application.
Study NCT06720129 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard care alone
Description: standard care plus a hydrocolloid dressing for protection
Study NCT06720220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: procedural sedation by I.V. infusion of dexmedetomidine. It was prepared as 200 ug (2 ml) of dexmedetomidine added to 48 ml of 0.9% saline.~A loading dose of dexmedetomidine 0.5 to 1 ug/kg was given over 10- 20 minutes, followed by 0.2-0.7 ug/kg/hr as a continuous infusion by a syringe pump. During the dexmedetomidine infusion, a spontaneous respiratory pattern was maintained, and the level of sedation achieved to a point of semi-sleep but responds to commands (equivalent to Modified Ramsay Sedation Scale score of 3).
Study NCT06720220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: procedural sedation by I.V. infusion of dexmedetomidine. It was prepared as 200 ug (2 ml) of dexmedetomidine added to 48 ml of 0.9% saline.~A loading dose of dexmedetomidine 0.5 to 1 ug/kg was given over 10- 20 minutes, followed by 0.2-0.7 ug/kg/hr as a continuous infusion by a syringe pump. During the dexmedetomidine infusion, a spontaneous respiratory pattern was maintained, and the level of sedation achieved to a point of semi-sleep but responds to commands (equivalent to Modified Ramsay Sedation Scale score of 3).
Study NCT06720220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulization
Description: nebulization session through a face mask nebulizer attached to an oxygen source. The nebulizer chamber was filled with 10 ml of 2% lidocaine (200 mg). The oxygen flow was adjusted at a rate of 8-10 L/min for 10-15 minutes.
Study NCT06720220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Atomization
Description: Airway topicalization by atomization (through a modification of McKenzie technique). This modification utilizes a 10-Fr suction catheter instead of 20-gauge cannula. This suction catheter was attached to oxygen tubing with a three-way stopcock. The oxygen tubing was attached to an oxygen source, which delivers a flow of 2-4 L/min. A 10-ml syringe filled with 10 ml of lidocaine 2% was attached to top port of the three-way stopcock.~Local anesthetic was injected via the syringe forming a jet- like spray for topicalization of the nasal and oral mucosa
Study NCT06720220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spray-As-You-Go
Description: airway topicalization method using the fiberoptic bronchoscope itself. The fiberoptic bronchoscope, preloaded with a 6.5 or 7 mm endotracheal tube, was passed under direct vision through the nose into the pharynx. Then 10-ml syringe containing 10 ml Lidocaine 2%, was attached to the working channel, and thus the local anesthetic was sprayed towards the mucosa of postnasal space and back of throat, while advancing the fiberscope. At the level of the epiglottis and around the vocal cords 2-4 ml of lidocaine 2% were sprayed toward these structures as the patient takes a deep breath to achieve sufficient anesthesia to the laryngeal inlet. The patient was asked to take another deep breath as the scope was passed through the vocal cords and 2 ml of lidocaine 2% is sprayed to the trachea and the scope was advanced further until the carina was visualized.
Study NCT06719986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene HCl injection
Description: Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
Study NCT06719986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone HCl intranasal
Description: Naloxone 4 mg for intranasal (IN) administration
Study NCT06720272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School nurse program
Description: The intervention consists in the introduction of a school-nurse program providing health care through education about rheumatic heart disease, assessment, intervention, and follow-up of group A beta-hemolytic streptococcal pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with rheumatic heart disease.
Study NCT06721182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: endovascular balloon occlusion of the aorta
Study NCT06720779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAK physio knee prosthesis protocol
Description: The exercise protocol designed for knee conditions is carried out through TRAK, the digital rehabilitation tool.
Study NCT06720779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee conventional rehabilitation program
Description: Exercise protocol with the methodology of conventional clinical practice.
Study NCT06720779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee conventional rehabilitation program
Description: Exercise protocol with the methodology of conventional clinical practice.
Study NCT05262244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
Study NCT05277909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The expert assessment of shoulder impairments and individualised treatment plan
Description: The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
Study NCT05277909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A minimal physiotherapeutic rehabilitation program delivered in a pamphlet
Description: This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
Study NCT06149455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of antibiotics
Description: Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
Study NCT06149455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of antibiotics
Description: Patients will be randomized to a short (2 days) or long (7 days) of pre-operative antibiotics, the choice of agent will be dependent upon bacterial sensitivities if available which is standard of care.
Study NCT05098730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
Study NCT05098730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strategy Training
Description: Strategy training is comprised of participant-selected activity based goals, self evaluation, global problem solving strategies, and therapist-delivered guided training. The strategy training therapist will guide participants using prompting questions, as well as work sheets that facilitate learning and aid the participants in implementing the process.
Study NCT06538376 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Portable Dynamic Digital Radiography (DDR)
Description: (DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication.
Study NCT06129279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFT group
Description: Preliminary tests will be carried out and then the 1st EFT session will be held.~After 30 days, the first final tests will be performed and then the second EFT session will be held.~After 30 days, only the 2nd final tests will be performed.
Study NCT05234047 — intervention group
Intervention type: PROCEDURE
Intervention: MDCT (multidetector computed tomography)
Description: MDCT will be performed at inclusion and after 2 years
Study NCT05234047 — intervention group
Intervention type: PROCEDURE
Intervention: Dual-energy X-ray absorptiometry
Description: DXA will be performed at inclusion, 1 and 2 years after inclusion
Study NCT05688800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
Study NCT05688800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 1 : pressure release technique
Description: Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
Study NCT05688800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 2: thoracic spine manipulation
Description: Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
Study NCT05552183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral dose of 200 mg pacritinib twice daily (BID)
Description: Subjects will receive 200 mg BID pacritinib for 14 days.
Study NCT05042128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSTA1
Description: LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
Study NCT05042128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Study NCT05781074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: a PD-1 immune checkpoint inhibitor
Study NCT05781074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules
Study NCT05781074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is performed under US or CT guidance per Investigator decision
Study NCT06004986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Administering Dupilumab 300 mg at different dosing intervals.
Study NCT05042128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine Injection
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Study NCT05042128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Chemotherapy drug provided as solution to be administered via IV infusion.
Study NCT05042128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab paclitaxel
Description: Chemotherapy drug provided as solution to be administered via IV infusion.